Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy combined with… changes local adverse effects ‐ perioperative retinal haemorrhages (unit of… compared with laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP by 55 weeks' PMA · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy combined with… may leads to lower recurrence of ROP by 55 weeks' postmenstrual age compared with laser/cryotherapy (low certainty).
1 finding from 1 review
Structural outcome ‐ complete retinal detachment (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes structural outcome ‐ complete retinal detachment (unit of analysis:… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Refractive error ‐ very high myopia ‐ at 30 months of age (unit of analysis: eyes) · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy may leads to lower refractive error ‐ very high myopia ‐ at 30 months of age (unit of… compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality before discharge from primary hospital compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Mortality at 30 months of age · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality at 30 months of age compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Local adverse effects ‐ corneal opacity requiring corneal transplant (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes local adverse effects ‐ corneal opacity requiring corneal transplant… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Local adverse effects ‐ lens opacity requiring cataract removal (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes local adverse effects ‐ lens opacity requiring cataract removal… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP (up to 6 months of age) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (up to 6 months of age) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (unit of analysis: eyes) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
≥ 50% reduction in seizure frequency 2‐month · children with SMEI
The intervention probably leads to higher ≥ 50% reduction in seizure frequency 2‐month (moderate certainty).
1 finding from 1 review
Intervention not reported
Seizure freedom 2‐month · children with SMEI
The intervention probably leads to higher seizure freedom 2‐month (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of dropouts 2‐month · children with SMEI
The intervention showed no clear difference in proportion of dropouts 2‐month (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects · children with SMEI
The intervention may leads to higher adverse effects (low certainty).
1 finding from 1 review
Intervention not reported
Disability‐worsening Proportion of participants with disability‐worsening at a maximum of five years'
It is very uncertain whether the intervention changes disability‐worsening Proportion of participants with… (very low certainty).
1 finding from 1 review
OR 0.88 [0.5, 1.57]
Studies not reported
Very low
Intervention not reported
Relapse Proportion of participants with relapse at a maximum of five years'
The intervention may leads to lower relapse Proportion of participants with relapse at a maximum of five… (low certainty).
1 finding from 1 review
OR 0.35 [0.26, 0.48]
Studies not reported
Low
Intervention not reported
Virological success · antiretroviral‐naïve individuals
The intervention showed no clear difference in virological success (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: pyrexia · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: pyrexia (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised transaminases · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: raised transaminases (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised alkaline phosphatase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised alkaline phosphatase (low certainty).
1 finding from 1 review